Strides Shasun has announced that it has received approval from the United States Food & Drug Administration (USFDA) for Abacavir tablets USP, 300 mg. The product will be launched immediately.
 
The product will be manufactured at the company’s USFDA approved facility at Bangalore and marketed by Strides in the US Market. According to IMS data, the US market for Abacavir is approximately USD 30 million.
 
Abacavir tablets is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents
 
The company has four business verticals: Regulated Markets, Emerging Markets, Institutional Business and Active Pharmaceutical Ingredients. It has a global manufacturing foot print with 13 manufacturing facilities spread across three continents including 5 US FDA approved facilities and 8 facilities for the emerging markets. It has three dedicated R&D facilities in India with global filing capabilities with a presence across 85 countries.